Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ELDN NASDAQ:FHTX NASDAQ:FLNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.10-13.9%$2.31$1.01▼$3.40$270.90M0.64469,475 shs719,048 shsELDNEledon Pharmaceuticals$3.88+0.5%$3.12$1.35▼$4.60$297.95M0.941.75 million shs1.11 million shsFHTXFoghorn Therapeutics$4.44+5.7%$5.08$3.27▼$6.95$246.60M2.97118,799 shs194,537 shsFLNACassava Sciences$1.30-4.4%$1.90$1.27▼$4.98$65.70M-0.75448,264 shs419,832 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+2.95%+0.83%+24.49%+138.05%ELDNEledon Pharmaceuticals0.00%+6.04%+23.32%+76.26%+28.58%FHTXFoghorn Therapeutics0.00%-11.58%-14.11%-26.06%+5.00%FLNACassava Sciences0.00%-6.21%-18.56%-33.00%-12.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.10-13.9%$2.31$1.01▼$3.40$270.90M0.64469,475 shs719,048 shsELDNEledon Pharmaceuticals$3.88+0.5%$3.12$1.35▼$4.60$297.95M0.941.75 million shs1.11 million shsFHTXFoghorn Therapeutics$4.44+5.7%$5.08$3.27▼$6.95$246.60M2.97118,799 shs194,537 shsFLNACassava Sciences$1.30-4.4%$1.90$1.27▼$4.98$65.70M-0.75448,264 shs419,832 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector0.00%+2.95%+0.83%+24.49%+138.05%ELDNEledon Pharmaceuticals0.00%+6.04%+23.32%+76.26%+28.58%FHTXFoghorn Therapeutics0.00%-11.58%-14.11%-26.06%+5.00%FLNACassava Sciences0.00%-6.21%-18.56%-33.00%-12.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.6372.62% UpsideELDNEledon Pharmaceuticals 2.40Hold$9.67149.14% UpsideFHTXFoghorn Therapeutics 2.89Moderate Buy$11.13150.56% UpsideFLNACassava Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest FLNA, ELDN, FHTX, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.004/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026ALECAlector Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight3/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026FHTXFoghorn Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/12/2026FHTXFoghorn Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$10.003/10/2026ALECAlector BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.003/10/2026FHTXFoghorn Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.002/17/2026FHTXFoghorn Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.00 ➝ $12.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M11.08N/AN/A$0.28 per share7.50ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/AFHTXFoghorn Therapeutics$30.91M8.43N/AN/A($1.92) per share-2.31FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-235.79%-38.19%N/AELDNEledon Pharmaceuticals-$45.62M-$0.52N/AN/AN/AN/A-85.61%-31.93%5/13/2026 (Estimated)FHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.91%5/13/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.88N/AN/AN/AN/A-51.71%-32.90%N/ALatest FLNA, ELDN, FHTX, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22N/AN/AN/AN/AN/A5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/12/2026Q4 2025FLNACassava Sciences-$0.30-$0.26+$0.04-$0.26N/AN/A3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 million2/25/2026Q4 2025ALECAlector-$0.39-$0.34+$0.05-$0.34$1.78 million$6.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.303.833.83ELDNEledon PharmaceuticalsN/A7.407.40FHTXFoghorn TherapeuticsN/A2.732.73FLNACassava SciencesN/A2.232.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ELDNEledon Pharmaceuticals56.77%FHTXFoghorn Therapeutics61.55%FLNACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%ELDNEledon Pharmaceuticals12.30%FHTXFoghorn Therapeutics7.58%FLNACassava Sciences44.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million100.26 millionOptionableELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionableFLNACassava Sciences2048.31 million26.62 millionOptionableFLNA, ELDN, FHTX, and ALEC HeadlinesRecent News About These CompaniesFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7 at 12:38 PM | finance.yahoo.comFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7 at 8:00 AM | globenewswire.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | finance.yahoo.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | globenewswire.comCassava Sciences (NASDAQ:SAVA) Stock Price Down 0.6% - Should You Sell?April 23, 2026 | marketbeat.comFilana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | finance.yahoo.comFilana leaves Cassava roots behind amid branch into epilepsyMarch 11, 2026 | fiercepharma.comFCassava Sciences to rebrand to Filana TherapeuticsMarch 10, 2026 | seekingalpha.comCassava Sciences Announces Name Change to Filana Therapeutics, Inc.March 10, 2026 | finance.yahoo.comCassava Sciences Rebrands as Filana Therapeutics, Updates TickerMarch 10, 2026 | tipranks.comWhy Cassava Sciences, Inc.’s (SAVA) Stock Is Up 6.02%February 24, 2026 | aaii.comACassava says DoJ has ended probe into research misconductFebruary 20, 2026 | seekingalpha.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 20, 2026 | finance.yahoo.comCassava Sciences stock rises after DOJ closes investigationFebruary 20, 2026 | za.investing.comCassava Sciences gains as DOJ ends probe into research misconduct claimsFebruary 20, 2026 | msn.comCassava Sciences says US DOJ has closed investigation into companyFebruary 20, 2026 | msn.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 19, 2026 | markets.businessinsider.comCassava Sciences And 2 Other Promising Penny StocksFebruary 11, 2026 | finance.yahoo.comCassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s DiseaseJanuary 13, 2026 | finance.yahoo.comHALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSDecember 24, 2025 | prnewswire.comCassava Sciences to pay $31.25M to settle securities class action litigationDecember 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLNA, ELDN, FHTX, and ALEC Company DescriptionsAlector NASDAQ:ALEC$2.10 -0.34 (-13.93%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.08 -0.02 (-1.00%) As of 05/8/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Eledon Pharmaceuticals NASDAQ:ELDN$3.88 +0.02 (+0.52%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.89 +0.01 (+0.26%) As of 05/8/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Foghorn Therapeutics NASDAQ:FHTX$4.44 +0.24 (+5.71%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.72 +0.28 (+6.31%) As of 05/8/2026 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Cassava Sciences NASDAQ:FLNA$1.30 -0.06 (-4.41%) As of 05/8/2026 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
